Product Information
EXFORGE 10-160 MG TABLET is a brand product labeled by Novartis Pharmaceuticals Corporation, priced at $12.1271 per EA under NDC 00078048915. Its NADAC has been published 394 times since Nov 28, 2013.
Strength
10; 160 mg/1; mg/1
Manufacturer
Novartis Pharmaceuticals CorporationNDC
00078048915
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Last Updated
1/7/2026
Active Ingredients
AMLODIPINE BESYLATE; VALSARTANApproval Type
New Drug (NDA)
FDA Application
NDA021990On Market Since
6/20/2007
Pharmacological Classes
Price Statistics
The NADAC for EXFORGE 10-160 MG TABLET has been published 394 times since Nov 28, 2013, and over the history we have for it it has risen 147.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $12.1271 per EA |
|---|---|
| All-time high | $12.1271 (Mar 11, 2026) |
| All-time low | $4.8984 (Nov 28, 2013) |
| 52-week high | $12.1271 |
| 52-week low | $11.7739 |
| Median price | $8.8837 |
| Average price | $8.5593 |
| Largest weekly change | +19.5% (Apr 15, 2015) |
| Weeks tracked | 394 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient, strength, and dosage form. Compare the broader picture on the amlodipine besylate and valsartan market page.
Lowest-Cost Alternatives
No alternatives available
Frequently asked questions
What is the NADAC price of EXFORGE 10-160 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for EXFORGE 10-160 MG TABLET, manufactured by Novartis Pharmaceuticals Corporation, is $12.1271 per EA (NDC 00078048915), effective Mar 11, 2026.
How has the price of EXFORGE 10-160 MG TABLET changed over time?
Over the history we have for it, the NADAC for EXFORGE 10-160 MG TABLET has risen 147.6%. It has been tracked across 394 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for EXFORGE 10-160 MG TABLET?
Since Nov 28, 2013, the NADAC for EXFORGE 10-160 MG TABLET has ranged from a low of $4.8984 (Nov 28, 2013) to a high of $12.1271 (Mar 11, 2026), with a median of $8.8837 per EA.
Are there cheaper alternatives to EXFORGE 10-160 MG TABLET?
No other NADAC-published product currently shares the active ingredient, strength, and dosage form of EXFORGE 10-160 MG TABLET, so no direct lower-cost alternative is listed.
Who manufactures EXFORGE 10-160 MG TABLET?
EXFORGE 10-160 MG TABLET (NDC 00078048915) is labeled by Novartis Pharmaceuticals Corporation, and CMS classifies it as a brand product.
Related Drugs
Same classification